The Emirates Drug Establishment (EDE) has officially sanctioned Baxfendy, an innovative treatment by AstraZeneca aimed at patients struggling with uncontrolled high blood pressure.
With this landmark decision, the UAE proudly stands as the first nation globally to approve the medication, a significant stride towards expediting access to state-of-the-art healthcare solutions and cutting-edge cardiovascular treatments.
Baxfendy incorporates the active compound baxdrostat and will be offered in dosages of 1 mg and 2 mg. This medication is intended to complement existing antihypertensive therapies for patients whose blood pressure remains uncontrolled despite other treatments.
The treatment functions by inhibiting an enzyme responsible for the production of aldosterone, a hormone associated with elevated blood pressure. By addressing the underlying issue of resistant hypertension, Baxfendy presents a targeted therapeutic option for patients unresponsive to standard treatments.
Dr. Fatima Al Kaabi, Director-General of the EDE, emphasized that this approval showcases the UAE's dedication to offering patients modern medical solutions and ensures expedited access to innovative drugs through adaptable regulatory pathways.
She mentioned that the EDE is committed to enhancing approval and accessibility processes in alignment with the nation's healthcare priorities, thus improving patient outcomes and fostering better management of chronic illnesses, particularly cardiovascular diseases.
Sameh El Fangary, Gulf Country President of AstraZeneca, applauded the approval, indicating it broadens treatment options for hypertension patients and underscores confidence in the robust scientific data supporting the drug.
He also reiterated the company's commitment to collaborate with healthcare stakeholders in the UAE to enhance patient access to pharmaceutical innovations and bolster long-term healthcare results.
The approval was backed by favorable findings from two Phase III clinical research trials, BaxHTN and Bax24. These studies indicated significant and clinically relevant reductions in blood pressure levels when Baxfendy was administered alongside routine treatments.
This landmark approval aligns with the UAE’s broader strategy to fortify pharmaceutical security, enhance healthcare system preparedness, and ensure enduring access to innovative treatments that promote public health and community wellness.
Vancouver’s massive Oakridge Park redevelopment project will officially open its shopping mall secti
Jon Bernthal reprises his role as Frank Castle in The Punisher: One Last Kill, streaming in India on
The Dubai Land Department launched phase two of the Emirati Real Estate Business Incubator to aid UA
Al Ramz Corporation debuts ARAM Capital in ADGM, aiming to provide comprehensive investment solution
